ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
Harnessing network pharmacology in drug discovery: an integrated approach.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Mechanistic elucidation ofJournal of ginseng research · 2026Article
- 7-Deshydroxypyrogallin-4-carboxylic acid dietary phytochemical as a putative FTO inhibitor in breast cancer: an integrated computational and cytotoxicity study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Natural Products Targeting Airway Inflammation and Mucus Hypersecretion: Molecular Mechanisms and Therapeutic Potential for Respiratory Health.Nutrients · 2026Review
- Quercetin Alleviates Neuroinflammation in Chronic Insomnia by Modulating the RAGE/NF-κB Signaling Pathway: Insights from Network Pharmacology and In Vitro Validation.Biomedicines · 2026Article
- Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.Pharmacological reports : PR · 2026Review
- Medicinal Chemistry Perspectives on Drug Repurposing: Innovative Approaches and Therapeutic Breakthrough.Therapeutic innovation & regulatory science · 2026Review
- Novel C3/C28-bis-1,2,4-Triazolyl-sulfanylacetate-betulin Derivatives: Synthesis and Evaluation of Anticancer Potential.International journal of molecular sciences · 2026Article
- Resveratrol synergizes with chloroquine to inhibit the malignant progression of oral squamous cell carcinoma by regulating KIF11.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Interpreting the Black Box: Interpretable Machine Learning and Systems Pharmacology in Small-Molecule Therapeutics.Pharmaceutics · 2026Review
- In-silico Exploration of the Possible Prolactin Pathway Related Targets of B. Monnieri against Triple Negative Breast Cancer: Selection of the Best Target Ligand Combination.Cell biochemistry and biophysics · 2026Article
- Review
- The effect of gentiopicroside on brain tissue repair in mice during the acute phase of middle cerebral artery occlusion.Molecular biology reports · 2026Article
- A novel mechanism for treating acute lung injury with ligustilide: elucidation via network pharmacology and in vitro validation.Journal of natural medicines · 2026Article
- From Algorithms to Assets: A Comprehensive Review of AI's Role in Preclinical Drug Discovery and the Hurdles to Clinical Translation.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Gene regulatory and biomolecular networks and their multifaceted biotechnological applications.World journal of microbiology & biotechnology · 2026Review
- Rethinking Nature's Pharmacy: AI Era and Natural Product Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Artificial Intelligence in Lung Cancer: A Narrative Review of Recent Advances in Diagnosis, Biomarker Discovery, and Drug Development.Pharmaceutics · 2026Review
- Characterization of rutin bindingto HRAS and MAPK3 and its clinical prognostic relevancein lung cancer: Using in silico and clinical prognostic experimental design.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Mechanistic Evaluation of Roxadustat for Pulmonary Fibrosis: Integrating Network Pharmacology, Transcriptomics, and Experimental Validation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Integrating network pharmacology, molecular docking, and experimental validation, this study explores the mechanism of action of Typhonii Rhizoma in colon cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional drug discovery approach is based on one drug-one target, that is associated with very lengthy timelines, high costs and very low success rates. Network pharmacology (NP) is a novel method of drug designing, that is based on a multiple-target approach. NP integrates systems such as biology, pharmacology and computational techniques to address the limitations of traditional methods of drug discovery. With help of mapping biological networks, it provides deep insights into biological molecules' interactions and enhances our understanding to the mechanism of drugs, polypharmacology and disease etiology. This review explores the theoretical framework of network pharmacology, discussing the principles and methodologies that enable the construction of drug-target and disease-gene networks. It highlights how data mining, bioinformatics tools and computational models are utilised to predict drug behaviour, repurpose existing drugs and identify novel therapeutic targets. Applications of network pharmacology in the treatment of complex diseases-such as cancer, neurodegenerative disorders, cardiovascular diseases and infectious diseases-are extensively covered, demonstrating its potential to identify multi-target drugs for multifaceted disease mechanisms. Despite the promising results, NP faces challenges due to incomplete and quality of biological data, computational complexities and biological system redundancy. It also faces regulatory challenges in drug approval, demanding revision in regulatory guidelines towards multi-target therapies. Advancements in AI and machine learning, dynamic network modelling and global collaboration can further enhance the efficacy of network pharmacology. This integrative approach has the potential to revolutionise drug discovery, offering new solutions for personalised medicine, drug repurposing and tackling the complexities of modern diseases.
Indexed as
Identifiers
39621088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.